Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats

Molecular Pharmacology

Volumn 67, Issue 1, 2005, Pages 204-211

  Gao, Yang ^a   Atanasova, Elena ^a   Sui, Nan ^a,c   Pancook, James D ^b   Watkins, Jeffry D ^b   Brimijoin, Stephen ^a  

^a MAYO CLINIC   (United States)

^b Applied Molecular Evolution   (United States)

^c INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHOLINESTERASE; COCAINE DERIVATIVE; COCAINE HYDROLASE; COMPLEMENTARY DNA; HYDROLASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; ENZYME ACTIVITY; ENZYME STABILITY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; MALE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOMETRY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

ANIMALS; BASE SEQUENCE; BRAIN; BUTYRYLCHOLINESTERASE; CARBOXYLIC ESTER HYDROLASES; COCAINE; DNA PRIMERS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; KINETICS; LIVER; LUNG; MYOCARDIUM; ORGAN SPECIFICITY; RATS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 11244266133     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.006924     Document Type: Article

References (25)

1. Altamirano C and Lockridge O (1999) Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact 119-120:53-60.
2. Amara SG and Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73-93.
3. Benowitz N (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72:3-12.
4. Brimijoin S, Mintz KP, and Alley M (1983) Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol 24:513-520.
5. Brimijoin S, Shen M, and Sun H (2002) Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem 309:200-205.
6. Carroll FI, Howell LL, and Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42:2721-2736.
7. Connelly S and Mech C (2004) Delivery of adenoviral DNA to mouse liver. Methods Mol Biol 246:37-52.
8. Dai Y, Schwarz EM, Gu D, Zhang WW, and Sarvetnick N (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization to factor IX adenovirus vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92:1401-1405.
9. Gao Y and Brimijoin S (2004) An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther 310:1046-1052.
10. Grimm D and Kay MA (2003) From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3:281-304.
11. Jakobsson J, Ericson C, Jansson M, Björk E, and Lundberg C (2003) Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res 73:876-885.
12. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-47.
13. Krejci E, Thomine S, Boschetti N, Legay C, Sketelj J, and Massoulie J (1997) The mammalian gene of acetylcholinesterase-associated collagen. J Biol Chem 272:22840-22847.
14. Kronman C, Velan B, Marcus D, Ordentlich A, Reuveny S, and Shafferman A (1995) Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation. Biochem J 311:959-967.
15. Pancook JD, Pecht G, Ader M, Mosko M, Lockridge O, and Watkins JD (2003) Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J 17:A565.
16. Ritz M, Lamb R, Goldberg S, and Kuhar M (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
17. Saxena A, Ashani Y, Raveh L, Stevenson D, Patel T, and Doctor B (1998) Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol Pharmacol 53:112-122.
18. Shah V, Chen A, Hendrickson H, Weiler D, Smith L, Yao J, and Katusic Z (2000) Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro. Am J Physiol 279:G1023-G1030.
19. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, and Pang YP (2001) Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem 276:9330-9336.
20. Sun H, Pang Y-P, Lockridge O, and Brimijoin S (2002a) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 621:220-224.
21. Sun H, Shen ML, Pang Y-P, Lockridge O, and Brimijoin S (2002b) Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther 302:710-716.
22. Thomas CE, Ehrhardt A, and Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346-358.
23. Weinshilboum R and Wang L-W (2004) Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 75:253-258.
24. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, and Lockridge O (1999) An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55:83-91.
25. Yang Y, Li Q, Ertl HCJ, and Wilson LM (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 67:2004-2015.